Valuation: Wockhardt Limited

Market Cap 309B 3.22B 2.76B 2.58B 2.36B 4.46B 4.51B 30.58B 11.89B 155B 12.1B 11.84B 513B P/E 2025
-472x
P/E 2026 89.7x
Enterprise Value 324B 3.39B 2.9B 2.71B 2.48B 4.68B 4.73B 32.12B 12.49B 163B 12.71B 12.44B 539B EV / Sales 2025
8.1x
EV / Sales 2026 5.97x
Free-Float
48.98%
Yield 2025 *
-
Yield 2026 -
1 day-0.07%
1 week+0.04%
Current month-3.07%
1 month+2.73%
3 months+20.58%
6 months+39.47%
Current year+31.35%
1 week 1,814.4
Extreme 1814.4
1,914.2
1 month 1,814.4
Extreme 1814.4
2,067.7
Current year 1,086.7
Extreme 1086.7
2,422.3
1 year 1,086.7
Extreme 1086.7
2,422.3
3 years 213.25
Extreme 213.25
2,422.3
5 years 145.15
Extreme 145.15
2,422.3
10 years 145.15
Extreme 145.15
2,422.3
Manager TitleAgeSince
Chief Executive Officer 53 2009-03-31
Director of Finance/CFO - 2022-02-28
Chief Tech/Sci/R&D Officer - 1998-04-30
Director TitleAgeSince
Chairman 83 2009-11-05
Director/Board Member 53 2009-11-05
Director/Board Member 55 1996-06-30
Change 5-day change 1-year change 3-year change Capi.($)
-0.07%+0.04%+28.40%+705.43% 3.23B
+0.63%+2.13%+17.07%+71.87% 47.86B
-0.98%+0.62%+49.89%+120.98% 40.33B
-1.11%-0.66%-10.72%+16.51% 12.13B
+1.88%-0.62%+13.72%+75.47% 11.5B
+0.19%0.00%+30.98%+154.90% 9.1B
+0.23%+3.33%+26.16%+45.77% 7.82B
+0.61%+2.10%+48.04%-11.10% 7.22B
+0.39%+3.05%+23.88%+220.36% 7.05B
+0.95%-9.11%-39.48%+14.70% 5.24B
Average +0.27%+0.28%+18.79%+141.49% 15.15B
Weighted average by Cap. +0.09%+0.90%+24.71%+98.89%

Financials

2025 2026
Net sales 30.35B 317M 272M 254M 232M 438M 443M 3.01B 1.17B 15.24B 1.19B 1.16B 50.42B 34.62B 362M 310M 290M 265M 500M 505M 3.43B 1.33B 17.38B 1.36B 1.33B 57.52B
Net income -470M -4.91M -4.21M -3.94M -3.6M -6.79M -6.86M -46.57M -18.11M -236M -18.43M -18.03M -781M 2.13B 22.24M 19.06M 17.83M 16.31M 30.77M 31.1M 211M 82.06M 1.07B 83.52M 81.71M 3.54B
Net Debt 14.33B 150M 128M 120M 110M 207M 209M 1.42B 552M 7.2B 562M 550M 23.81B 15.53B 162M 139M 130M 119M 224M 227M 1.54B 598M 7.8B 609M 596M 25.8B
Logo Wockhardt Limited
Wockhardt Limited is a research-based global pharmaceutical and biotech company. The Company is engaged in the pharmaceutical business. It focuses on the unmet need for antibacterial drugs that are effective against the menace of untreatable superbugs. It manufactures and supplies branded and generic finished formulations, as well as intermediate products like active pharmaceutical ingredients (APIs), worldwide. The Company’s products in India include EMROK, MERIWOK, REINVEXIN, ERLISO, METHYCOBAL 500 MCG 15T, METHYCOBAL INJ 1 ML, METHYCOBAL D 10T, HAPID 10C, PROXYFEN NANO GEL, LIVATIRA 500 10T NEW PACK, LIVATIRA INJ 5 ml, GABAWOK NT 100MG 15T, GABAWOK NT 400MG 15T, ETOBRIX 90 MG 10C, ETOBRIX TH 4 10C, ETOBRIX P 10T, GLARZEN 100IU, TERITIDE, GLIMADAY HS, GLIMADAY FORTE-2, GLIMADAY FORTE-1, GLIMADAY FORTE 3, GLIMADAY 2 mg, GLIMADAY 1 mg, MOPADAY FORTE, INOGLA, WEPOX 4000 IU 1ML, MYCORAL M, Val 450, OKERON INJ 100MCG 1ML, DARBOTIN 40, and DARBOTIN 60.
Employees
2,564
Date Price Change Volume
26-08-25 1,899.60 -0.07% 241,579
26-08-24 ₹1,901.00 +0.78% 306,988
26-08-21 ₹1,886.30 +3.04% 559,221
26-08-20 ₹1,830.60 +0.25% 258,015
26-08-19 ₹1,826.00 -1.82% 503,577
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BB
  1. Stock Market
  2. Stocks
  3. WOCKPHARMA Stock